0204 ECP Apros
BioCentury & Getty Images

Emerging Company Profile

Apros: Engineering tissue-targeted TLR agonists

Emerging Company Profile: Apros is developing a pipeline of five TLR7 agonists targeting different tissues

Apros aims to increase the safety and tolerability of TLR agonists using a tissue-targeted approach, with lead candidate APR003 in Phase I to treat advanced colorectal cancer.

Feb 5, 2021 | 1:04 AM GMT

Apros is developing a suite of tissue-targeted TLR7 agonists for indications ranging from cancer to infectious disease that aim to avoid systemic toxicities that have plagued the drug class. 

Lead candidate APR003, a TLR7 agonist designed to home

Read the full 960 word article

How to gain access

Continue reading with a
two-week free trial.